Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …

Introduction Respiratory syncytial virus (RSV) is associated with significant morbidity
worldwide, especially among infants. We evaluated the potential impact of prophylactic …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the
United States. In August 2023, CDC's Advisory Committee on Immunization Practices …

Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …

Background Despite passive immunization with palivizumab to select high-risk children
under two years of age, the health and economic burden of respiratory syncytial virus (RSV) …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting …

Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

Background Palivizumab, a monoclonal antibody and the only licensed immunization
product for preventing respiratory syncytial virus (RSV) infection, is recommended for …

Background The cost-effectiveness of immunisation strategies with a long-acting
monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV …